Compare · BAX vs MDT
BAX vs MDT
Side-by-side comparison of Baxter International Inc. (BAX) and Medtronic plc. (MDT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. BAX focuses on Medical/Dental Instruments, while MDT focuses on Biotechnology: Electromedical & Electrotherapeutic Apparatus.
- MDT is the larger of the two at $104.85B, about 10.5x BAX ($10.01B).
- MDT has been more active in the news (16 items in the past 4 weeks vs 5 for BAX).
- Both have 25 recent analyst ratings on file.
- Company
- Baxter International Inc.
- Medtronic plc.
- Price
- $19.37+0.05%
- $81.64-0.34%
- Market cap
- $10.01B
- $104.85B
- 1M return
- +14.14%
- -
- 1Y return
- -37.21%
- -
- Industry
- Medical/Dental Instruments
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 5
- 16
- Recent ratings
- 25
- 25
Baxter International Inc.
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. It also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Latest BAX
- SVP, Interim CFO, CAO & Cntrlr Zielinski Anita A was granted 13,426 shares, increasing direct ownership by 29% to 59,714 units (SEC Form 4)
- President, Adv. Surgery Wallace Steven P. covered exercise/tax liability with 153 shares, decreasing direct ownership by 0.22% to 70,128 units (SEC Form 4)
- President, CCS Teaff James covered exercise/tax liability with 321 shares, decreasing direct ownership by 1% to 31,063 units (SEC Form 4)
- SEC Form SD filed by Baxter International Inc.
- Baxter downgraded by Citigroup with a new price target
- SEC Form S-8 filed by Baxter International Inc.
- Baxter International Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
- Director Wilkes David S. was granted 12,836 shares, increasing direct ownership by 53% to 37,076 units (SEC Form 4)
- Director Wendell Amy Mcbride was granted 12,836 shares, increasing direct ownership by 41% to 44,235 units (SEC Form 4)
- Director Schlichting Nancy M was granted 12,836 shares, increasing direct ownership by 58% to 34,994 units (SEC Form 4)
Latest MDT
- Medtronic upgraded by BTIG Research with a new price target
- Medtronic submits 510(k) filings to expand Hugo™ robotic-assisted surgery system into general and gynecologic specialties in the United States
- Medtronic announces strategic investments to support future expansion of cardiac ablation portfolio as physician demand for Affera™ technologies broadens
- Medtronic plc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Medtronic reports fourth quarter and full year fiscal 2026 results; delivers highest annual revenue growth in 10 years
- morph Launches the World's First Shapeshifting Soft Robotics Cells Platform to Bring Physical AI into Real-World Applications
- SVP, Chief HR Officer Walter Matthew R. converted options into 9,149 units of Ordinary Shares, increasing direct ownership by 28% to 41,529 units (SEC Form 4)
- EVP & Pres Neuroscience Wall Brett A. converted options into 26,907 units of Ordinary Shares, increasing direct ownership by 49% to 82,183 units (SEC Form 4)
- Chairman and CEO Martha Geoffrey converted options into 94,963 units of Ordinary Shares, increasing direct ownership by 38% to 343,099 units (SEC Form 4)
- EVP, Pres MedSurg and Americas Marinaro Michael converted options into 18,994 units of Ordinary Shares, increasing direct ownership by 37% to 70,593 units (SEC Form 4)